IBL International Competitors and Similar CompaniesClear all
IBL International's competitors and similar companies include BioCryst Pharmaceuticals, Fortress Biotech, OriGene Technologies and CANbridge Life Sciences.
 IBL International IBL International is a company that develops, produces, and sells immunodiagnostic products. |  BioCryst Pharmaceuticals BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases. |  Fortress Biotech Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. |  CANbridge Life Sciences CANbridge Life Sciences is a biopharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions. | ||
Founding Date | Founding Date 1983 | Founding Date 1986 | Founding Date 2006 | Founding Date 1996 | Founding Date 2012 |
Type | Type Subsidiary | Type Public | Type Public | Type Subsidiary | Type Private |
Tags | |||||
Locations | Locations Hamburg, DE HQ Morrisville, US | Locations Durham, US HQ Hoover, US | Locations New York, US HQ Waltham, US | Locations Rockville, US HQ Herford, DE Newark, US Windham, US | Locations CN HQ Hangzhou Shi, CN Cambridge, US |
Employees | Employees 502% decrease | Employees 14040% increase | Employees 10146% decrease | Employees 1242% increase | Employees 506% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.7 b | Valuation ($) 55.7 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $874.8m (FY, 2025) | Revenue (est.) $63.3m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $19.1m (FY, 2025) | Cost of goods $20.9m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $855.8m (FY, 2025) | Gross profit $42.3m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income $263.9m (FY, 2025) | Net income ($32.9m) (FY, 2025) | Net income N/A | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.9m | Total funding raised N/A | Total funding raised $ 69.6m | Total funding raised $ 224.1m |
For sources of this data, please see the company profile
View Company Profiles
BioCryst Pharmaceuticals
HQ
Durham, US
Employees
140↑ 40% increase
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases.
View companyFortress Biotech
HQ
New York, US
Employees
101↓ 46% decrease
Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products.
View company
OriGene Technologies
HQ
Rockville, US
OriGene Technologies is a company specializing in biotechnology research.
View companyCANbridge Life Sciences
HQ
CN
Employees
50↓ 6% decrease
CANbridge Life Sciences is a biopharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions.
View company